Estrogen Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-01-25Clinical Trial Update: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer [Phase 1]
A Phase 1 study evaluating the combination of BKM-120 (buparlisib) and fulvestrant in postmenopausal patients with estrogen receptor-positiv…
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms [Phase 2]
Phase 2 clinical trial evaluating zoledronic acid for aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients has com…
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) [Phase 2]
Phase II study evaluating androgen receptor–targeted therapy in pre-treated postmenopausal patients with ER/PR status and AR positivity in m…
-
CLINICAL_TRIALS trial_result · 2016-09-22Clinical Trial Update: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer [Phase 3]
A Phase 3 trial assessed ovarian function suppression with tamoxifen or exemestane versus tamoxifen alone in premenopausal women with hormon…
-
CLINICAL_TRIALS research · 2016-07-20Clinical Trial Update: (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer
This clinical trial update discusses the use of the Oncotype DX genomic test in estrogen receptor-positive, HER2-negative breast cancer with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-06-20Clinical Trial Update: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer [Phase 2]
Phase 2 trial evaluating eribulin in combination with capecitabine as adjuvant therapy for estrogen receptor–positive early-stage breast can…
-
CLINICAL_TRIALS trial_result · 2016-03-14Clinical Trial Update: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating preoperative MM-121 with Paclitaxel in HER2-negative breast cancer completed; results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-02-11Clinical Trial Update: Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Phase 1, Phase 2]
A Phase 1/2 trial evaluating AZD4547 in combination with Fulvestrant versus Fulvestrant alone in estrogen receptor-positive breast cancer ha…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer [NA]
This clinical trial update reports on evaluating whether the Breast Cancer Index influences decisions to extend adjuvant endocrine therapy i…
-
CLINICAL_TRIALS trial_result · 2015-11-05Clinical Trial Update: An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer [Phase 2]
Open-label Phase 2 window-of-opportunity study evaluating ganetespib in women with breast cancer has completed.
-
CLINICAL_TRIALS research · 2015-10-28Clinical Trial Update: An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients
An observational study evaluating how patients with estrogen receptor-positive breast cancer respond to tamoxifen.
-
CLINICAL_TRIALS trial_result · 2015-08-10Clinical Trial Update: Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial investigating tipifarnib and fulvestrant in hormone receptor-positive metastatic breast cancer has completed with res…
-
CLINICAL_TRIALS trial_result · 2015-07-21Clinical Trial Update: 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ [Phase 2]
A Phase 2 clinical trial evaluating 4-Hydroxytamoxifen or Tamoxifen Citrate for newly diagnosed Ductal carcinoma in situ (DCIS) in women, wi…
-
CLINICAL_TRIALS trial_result · 2015-06-17Clinical Trial Update: Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive [Phase 3]
Phase 3 trial evaluating fulvestrant with or without lapatinib in postmenopausal women with hormone receptor–positive, HER2-positive advance…
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer [Phase 2]
Phase 2 trial evaluating goserelin with letrozole or anastrozole in premenopausal women with stage II-III estrogen receptor-positive breast …
-
CLINICAL_TRIALS trial_result · 2014-12-25Clinical Trial Update: F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating F-18 16 alpha-fluoroestradiol PET to predict response to first-line hormone therapy in patients with stage…
-
CLINICAL_TRIALS trial_result · 2014-12-03Clinical Trial Update: Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen [Phase 2]
A Phase 2 study evaluated the combination of lapatinib and tamoxifen in patients with locally advanced or metastatic breast cancer that prog…
-
CLINICAL_TRIALS trial_result · 2013-12-31Clinical Trial Update: Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women [Phase 2]
A Phase 2 trial is evaluating Letrozole with a CDK 4/6 inhibitor in postmenopausal women with estrogen receptor-positive, HER2-negative brea…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer [Phase 1]
Phase 1 trial evaluating RO4929097 in combination with letrozole for postmenopausal women with estrogen receptor-positive, HER2-negative bre…
-
CLINICAL_TRIALS trial_result · 2013-07-17Clinical Trial Update: Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
AstraZeneca-sponsored epidemiology study in postmenopausal women with estrogen receptor-positive breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2011-05-06Clinical Trial Update: Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer [Phase 2]
A Phase 2 study comparing anastrozole plus gefitinib to fulvestrant plus gefitinib in postmenopausal women with metastatic breast cancer; re…
-
CLINICAL_TRIALS trial_result · 2008-06-12Clinical Trial Update: Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating fulvestrant (FASLODEX) as a treatment for postmenopausal women with estrogen receptor-positive breast ca…